President Obama's all-out effort to wrest the health care conversation from the right wing and more at the Health Reform Insider, Community Catalyst's weekly take on what's happening in national reform. --Kate Petersen

Largest criminal fine imposed by US in any matter    Last week, the Department of Justice (DOJ) announced that its investigaton and several whistle-blower, or qui tam lawsuits had lead to a $2.3 billion dollar settlement resolving the alleged criminal and

Documents that have surfaced about Medtronic’s marketing strategies down under shed more light on the Fridley, Minn.–based medical device company’s marketing operation in Australia and the lengths it has gone to get its product in the operating room. The

For days, the tension has been mounting over what President Obama would say when he addressed the nation on health care.  Last night, with an eloquent prime time address to a joint session of Congress, the President powerfully rebooted the debate on healt

Today, Community Catalyst proudly launches our new blog, Health Policy Hub. While the word "policy" may sound a bit wonky to some, we hope to hit the wonk-life balance by providing interesting commentary on all things health care without coming off like p

A health reform proposal presented today to members of the Senate Finance Committee would bring new transparency to financial relationships between drug or device companies and the medical profession. A form of the Physician Payments Sunshine Act was incl

Bextra, Bextra! This week, the Dept. of Justice announced that Pfizer will pay $2.3B in civil and criminal penalties for off-label marketing of four drugs.  The settlement, which alleges that off-label marketing tactics led to over-prescribing of Bextra,

Through several consumer-focused class action lawsuits, we have seen numerous deceptive schemes by different players in the drug industry to manipulate the complex national drug pricing system for profit.  One solution to these fraudulent and deceptive sc

In an article published yesterday in the New Ledger, the American Enterprise Institute's Roger Bate contends that the industry's line on the safety of buying drugs online (they say it isn't) is largely overblown. Bate describes his recent study of drugs p